Journal of clinical lipidology最新文献_第9页

Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: Evidence from the National FH PASS database. 识别英国家族性高胆固醇血症患者的挑战与机遇：来自全国家族性高胆固醇血症 PASS 数据库的证据。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1016/j.jacl.2024.08.007

Edward Cox, Rita Faria, Pedro Saramago, Kate Haralambos, Melanie Watson, Steve E Humphries, Nadeem Qureshi, Beth Woods

{"title":"Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: Evidence from the National FH PASS database.","authors":"Edward Cox, Rita Faria, Pedro Saramago, Kate Haralambos, Melanie Watson, Steve E Humphries, Nadeem Qureshi, Beth Woods","doi":"10.1016/j.jacl.2024.08.007","DOIUrl":"10.1016/j.jacl.2024.08.007","url":null,"abstract":"<p><strong>Background: </strong>Familial hypercholesterolemia (FH) is a monogenic disorder that causes high levels of low-density lipoprotein (LDL) cholesterol. Cascade testing, where relatives of known individuals with FH ('index') are genetically tested, is effective and cost-effective, but implementation in the UK varies.</p><p><strong>Objective: </strong>This study aims to provide evidence on current UK FH cascade yields and to identify common obstacles cascade services face and individual- and service-level predictors of success.</p><p><strong>Methods: </strong>Electronic health records from 875 index families and 5,958 linked relatives in the UK's Welsh and Wessex FH services (2019) were used to explore causes for non-testing and to estimate testing rates, detection yields, and how relative characteristics and contact methods relate to the probability of relatives being tested (using logistic regression).</p><p><strong>Results: </strong>In Wales (Wessex), families included 7.35 (7.01) members on average, with 2.41 (1.66) relatives tested and 1.35 (0.96) diagnosed with FH per index. Cascade testing is limited by individualized circumstances (too young, not at-risk, etc.) and FH services' reach, with approximately one in four relatives out-of-area. In Wales, first-degree relatives (odds ratio (OR): 1.55 [95% confidence interval (CI): 1.28, 1.88]) and directly contacted relatives (OR: 2.11 [CI: 1.66, 2.69]) were more likely to be tested. In Wales and Wessex, women were more likely to be tested than men (ORs: 1.53 [CI: 1.28, 1.85] and 1.74 [CI: 1.32, 2.27]).</p><p><strong>Conclusion: </strong>In Wales and Wessex less than a third of relatives of an index are tested for FH. Improvements are likely possible by integrating geographically dispersed families into cascade testing, services directly contacting relatives where possible, and finding new ways to encourage participation, particularly amongst men.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":"e1046-e1054"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monocyte/lymphocyte ratio as a risk factor of cardiovascular and all-cause mortality in coronary artery disease with low-density lipoprotein cholesterol levels below 1.4 mmol/L: A large longitudinal multicenter study. 单核细胞/淋巴细胞比率作为低密度脂蛋白胆固醇水平低于 1.4 mmol/L 的冠心病患者心血管疾病和全因死亡率的风险因素：一项大型纵向多中心研究。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-11-01 Epub Date: 2024-08-30 DOI: 10.1016/j.jacl.2024.08.005

Rengui Jiang, Huangtao Ruan, Wanying Wu, Yueting Wang, Haozhang Huang, Xiaozhao Lu, Weipeng Liang, Yang Zhou, Jielan Wu, Xianlin Ruan, Jinming Chen, Weipeng Zhang, Yulong Xiang, Zhitao Yan, Yong Liu, Ning Tan

{"title":"Monocyte/lymphocyte ratio as a risk factor of cardiovascular and all-cause mortality in coronary artery disease with low-density lipoprotein cholesterol levels below 1.4 mmol/L: A large longitudinal multicenter study.","authors":"Rengui Jiang, Huangtao Ruan, Wanying Wu, Yueting Wang, Haozhang Huang, Xiaozhao Lu, Weipeng Liang, Yang Zhou, Jielan Wu, Xianlin Ruan, Jinming Chen, Weipeng Zhang, Yulong Xiang, Zhitao Yan, Yong Liu, Ning Tan","doi":"10.1016/j.jacl.2024.08.005","DOIUrl":"10.1016/j.jacl.2024.08.005","url":null,"abstract":"<p><strong>Background and aims: </strong>The monocyte/lymphocyte ratio (MLR), an inflammatory marker, has an unclear relationship with the risk of residual inflammation in patients with coronary artery disease (CAD) and low-density lipoprotein cholesterol (LDL-C) below 1.4 mmol/L. This study aimed to assess the association between the MLR and cardiovascular and all-cause mortalities in these patients.</p><p><strong>Methods: </strong>A total of 2747 patients diagnosed with CAD via coronary angiography (CAG) and presenting with LDL-C levels < 1.4 mmol/L were enrolled in this observational study conducted from January 2007 to December 2020. Patients were categorized into four groups based on the MLR quartiles. We used Kaplan-Meier analysis and Cox regression models to evaluate the relationship between baseline MLR and cardiovascular and all-cause mortalities.</p><p><strong>Results: </strong>Among the 2747 participants followed up for a median duration of 6 years, there were 184 cardiovascular and 462 all-cause deaths. Elevated MLR levels were found to be associated with an increased risk of both cardiovascular and all-cause mortalities according to the Kaplan-Meier analysis. Multivariate Cox regression analysis demonstrated a significant association between higher MLR and an elevated risk of cardiovascular and all-cause mortality. Compared to the older group, with an increase in MLR levels, the younger group showed a higher hazard ratio for cardiovascular death. Similar results were obtained in the single-vessel disease group.</p><p><strong>Conclusions: </strong>In patients with CAD and LDL-C levels < 1.4 mmol/L, MLR can serve as a risk factor for both cardiovascular and all-cause mortalities owing to the risk of residual inflammation.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":"e986-e994"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical and demographic characteristics of patients with late-diagnosed cerebrotendinous xanthomatosis in a Turkish population. 土耳其晚期诊断的脑黄疽患者的临床和人口特征。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-11-01 Epub Date: 2024-08-31 DOI: 10.1016/j.jacl.2024.08.010

Huseyin Bilgin, Ilyas Yolbas, Selahattin Tekes

{"title":"The clinical and demographic characteristics of patients with late-diagnosed cerebrotendinous xanthomatosis in a Turkish population.","authors":"Huseyin Bilgin, Ilyas Yolbas, Selahattin Tekes","doi":"10.1016/j.jacl.2024.08.010","DOIUrl":"10.1016/j.jacl.2024.08.010","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to examine the clinical, laboratory and demographic characteristics of patients diagnosed with cerebrotendinous xanthomatosis (CTX).</p><p><strong>Materials and methods: </strong>This study included 11 patients followed up in the Pediatric Metabolism Polyclinic for a diagnosis of CTX. The diagnosis of CTX was made from high blood cholestanol level and CYP27A1 gene analysis. All the cases diagnosed with CTX for whom clinical and laboratory findings were evaluated were included in the study.</p><p><strong>Results: </strong>Evaluation was made of 11 patients from five different families. The diagnosis was established 25 years after symptoms first appeared. The diagnosis was made because of bilateral cataracts in two patients, tendon xanthomas in two, and as a result of family screening in seven. Tendon xanthomas were present in 36.3% of the patients, and there was a history of cataract in 54.5%. In the current study, mental retardation was determined in 72% of the patients, psychiatric findings in 36%, epilepsy in 36%, pyramidal-extrapyramidal findings in 45%, and postural tremor in 54%. In addition, neuropsychiatric symptoms were seen at different rates in patients with different gene alleles. No tendon xanthomas were determined in the cases with c.1263 + 4A>T and c.808C>T mutations. Cataract was determined in all the cases with homozygote c.1263 + 4A>T mutation.</p><p><strong>Conclusion: </strong>In this study, it was determined that the cases were diagnosed late despite the onset of symptoms providing clues for diagnosis at an early age. It was determined that the delay in diagnosis was 25 years.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":"e1067-e1073"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between changes in high-density lipoprotein cholesterol and risk of cardiovascular disease. 高密度脂蛋白胆固醇的变化与心血管疾病风险之间的关系。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-11-01 Epub Date: 2024-09-11 DOI: 10.1016/j.jacl.2024.09.001

Ya Wang, Tao Yan, Yuxin Yang, Lehui Li, Ziying Zhang, Xiaodong Cao, Yuan Xia, Yuan Shen, Kun Liu, Lei Xu, Chunfa Zhang, Xingguang Zhang, Nan Zhang

{"title":"Association between changes in high-density lipoprotein cholesterol and risk of cardiovascular disease.","authors":"Ya Wang, Tao Yan, Yuxin Yang, Lehui Li, Ziying Zhang, Xiaodong Cao, Yuan Xia, Yuan Shen, Kun Liu, Lei Xu, Chunfa Zhang, Xingguang Zhang, Nan Zhang","doi":"10.1016/j.jacl.2024.09.001","DOIUrl":"10.1016/j.jacl.2024.09.001","url":null,"abstract":"<p><strong>Background: </strong>The present study was performed to determine the association between changes in the high-density lipoprotein cholesterol (HDL-C) concentration and incident cardiovascular disease (CVD).</p><p><strong>Methods: </strong>Time-dependent Cox regression models were used to evaluate the association between changes in the HDL-C concentration and the risk of incident CVD. Participants were followed up from 2015 to 2021.</p><p><strong>Results: </strong>In total, 24,123 participants with a median follow-up of 4.26 years were analyzed, and the mean age of the cohort was 56.24 years, 57.8% were female, 24.3% were current smokers, and 12.8% had a history of alcohol use. Low, normal, and high HDL-C was defined as < 40, 40-80, and > 80 mg/dL, respectively. The average time for the two HDL-C measurements was 2.8 years. Compared with participants whose HDL-C was maintained at a normal level, the risk of CVD was higher in those whose HDL-C changed to a low level, remained unchanged at a low level (HR, 1.24; 95% CI, 1.01-1.40, P < 0.001), similarly, the risk of CVD was higher in those whose HDL-C changed from very high level to normal level (HR, 0.81; 95% CI, 0.67-0.99, P = 0.039). Also compared with participants whose HDL-C was maintained at a normal level, the risk of CVD was lower in those whose HDL-C increased from low to normal and high (HR, 0.80; 95% CI, 0.66-0.98, P = 0.029).</p><p><strong>Conclusions: </strong>Participants whose HDL-C changed to a low level and whose low HDL-C level was maintained had a higher risk of CVD, whereas participants whose HDL-C changed from low to high had a lower risk of CVD.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":"e1025-e1034"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII. 来自编辑：家族性乳糜微粒血症综合征即将到来的治疗：抑制载脂蛋白CIII产生的药物。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-11-01 Epub Date: 2024-12-09 DOI: 10.1016/j.jacl.2024.12.001

P Barton Duell, Kevin C Maki

引用次数: 0

Akira Endo (1933-2024), In Memoriam. 远藤明（Akira Endo，1933-2024 年），《悼念》。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-09-14 DOI: 10.1016/j.jacl.2024.09.004

W Virgil Brown, Ernst J Schaefer, Antonio M Gotto

引用次数: 0

The therapeutic effect of liver transplantation in 14 children with homozygous familial hypercholesterolemia: a prospective cohort: Liver transplant for familial hypercholesterolemia. 肝移植对 14 名同型家族性高胆固醇血症患儿的治疗效果：前瞻性队列：家族性高胆固醇血症的肝移植。

IF 4.4 3区医学

Journal of clinical lipidology Pub Date : 2024-09-05 DOI: 10.1016/j.jacl.2024.08.008

Dongni Lin,Yefeng Lu,Bijun Qiu,Mingxuan Feng,Yi Luo,Feng Xue,Tao Zhou,Jianjun Zhu,Jianjun Zhang,Lvya Wang,Qiang Xia,Ping Wan

{"title":"The therapeutic effect of liver transplantation in 14 children with homozygous familial hypercholesterolemia: a prospective cohort: Liver transplant for familial hypercholesterolemia.","authors":"Dongni Lin,Yefeng Lu,Bijun Qiu,Mingxuan Feng,Yi Luo,Feng Xue,Tao Zhou,Jianjun Zhu,Jianjun Zhang,Lvya Wang,Qiang Xia,Ping Wan","doi":"10.1016/j.jacl.2024.08.008","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.08.008","url":null,"abstract":"OBJECTIVESHomozygous familial hypercholesterolemia (HoFH) is characterized by elevated low-density lipoprotein cholesterol (LDL-C) and early-onset cardiovascular disease. To assess the therapeutic effects of liver transplantation (LT) on HoFH patients, we observed and analyzed the outcomes of HoFH children after LT.STUDY DESIGNThis prospective cohort study included all LT candidates under 18 years old diagnosed with HoFH at Ren Ji Hospital between November 2017 and July 2021. The patients were followed until October 2023. They were treated according to the standard protocol at our center. We collected data on changes in lipid profiles, clinical manifestations, and cardiovascular complications at different time points, and recorded postoperative recipient and graft survival.RESULTSFourteen HoFH patients with a median age of 7 (2-12) years were included. Preoperatively, xanthomas and arcus corneas occurred in 14 and 3 patients, respectively, with 10 patients showing mild cardiovascular disease. All patients underwent LT. Recipient and graft survival rates were 100 % over a median follow-up duration of 35 (27-71) months. Median LDL-C levels dropped from 11.83 (7.99-26.14) mmol/L preoperatively to 2.3 (1.49-3.39) mmol/L postoperative at the last measurement. Thirteen patients discontinued lipid-lowering treatment after LT, while only one patient resumed statins 6 months post-operation. Xanthomas and arcus corneas significantly improved. Cardiovascular complications regressed in five patients, with no progression observed in the others.CONCLUSIONSLT is a safe and effective treatment for severe HoFH patients beyond lipid-lowering control. Early LT improves prognosis and quality of life while minimizing the risk of cardiovascular complications.","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"2013 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The joint association of lipoprotein(a) and lipoprotein-associated phopholipase A2 with the risk of stroke recurrence 脂蛋白（a）和脂蛋白-PLA2 与中风复发风险的共同关系

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-09-01 DOI: 10.1016/j.jacl.2024.04.133

Jing Xue MD, PhD , Yukun Xiang MD , Xue Jiang PhD , Aoming Jin PhD , Xiwa Hao MD, PhD , Ke Li MD , Jinxi Lin PhD , Xia Meng MD, PhD , Hao Li PhD , Lemin Zheng PhD , Yongjun Wang MD, PhD , Jie Xu MD, PhD

{"title":"The joint association of lipoprotein(a) and lipoprotein-associated phopholipase A2 with the risk of stroke recurrence","authors":"Jing Xue MD, PhD , Yukun Xiang MD , Xue Jiang PhD , Aoming Jin PhD , Xiwa Hao MD, PhD , Ke Li MD , Jinxi Lin PhD , Xia Meng MD, PhD , Hao Li PhD , Lemin Zheng PhD , Yongjun Wang MD, PhD , Jie Xu MD, PhD","doi":"10.1016/j.jacl.2024.04.133","DOIUrl":"10.1016/j.jacl.2024.04.133","url":null,"abstract":"<div><h3>BACKGROUND AND PURPOSE</h3><div>Currently little is known about the joint association of lipoprotein (a) [Lp(a)] and lipoprotein-associated phospholipase A2 (Lp-PLA2) with stroke recurrence.</div></div><div><h3>METHODS</h3><div>In this prospective multicenter cohort study, 10,675 consecutive acute ischemic stroke (IS) and transient ischemic attack (TIA) patients with Lp(a) and Lp-PLA2 were enrolled. The association of stroke recurrence within 1 year with Lp(a) and Lp-PLA2 was assessed using Cox proportional hazards models and Kaplan-Meier curves. The interaction between Lp(a) and Lp-PLA2 with stroke recurrence was evaluated by multiplicative and additive scales.</div></div><div><h3>RESULTS</h3><div>A significant joint association of Lp(a) and Lp-PLA2 with the risk of stroke recurrence was observed. Multivariate Cox regression analysis demonstrated that the combination of elevated Lp(a) (≥ 50 mg/dL) and Lp-PLA2 (≥175.1 ng/mL) was independently associated with the risk of stroke recurrence (adjusted hazard ratio: 1.42; 95% confidence interval [CI]: 1.15–1.76). Both significant multiplicative [(exp(β3): 1.63, 95% CI: 1.17–2.29, <em>P</em> = 0.004] and additive interaction (RERI: 0.55, 95% CI: 0.20–0.90, <em>P</em> = 0.002; AP: 0.39, 95% CI, 0.24–0.53) were observed between Lp(a) and Lp-PLA2.</div></div><div><h3>CONCLUSIONS</h3><div>Our results indicated that Lp(a) and Lp-PLA2 have a joint association with the risk of stroke recurrence in IS/TIA patients. Patients with concomitant presence of elevated Lp(a) and Lp-PLA2 have greater risk of stroke recurrence.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 5","pages":"Pages e729-e737"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141025059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NLA Expert Clinical Consensus on apolipoprotein B recommends expanded clinical use and improved patient access NLA 载脂蛋白 B 专家临床共识建议扩大临床应用并改善患者就医途径。

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-09-01 DOI: 10.1016/j.jacl.2024.09.006

Kevin C. Maki PhD, P. Barton Duell MD

引用次数: 0

Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis 在接受和未接受脂蛋白清除术治疗的同型家族性高胆固醇血症患者中使用依维莫司的长期疗效和安全性的实际经验

IF 3.6 3区医学

Journal of clinical lipidology Pub Date : 2024-09-01 DOI: 10.1016/j.jacl.2024.05.006

Claudia Stefanutti MD, PhD , Dick C. Chan PhD , Giovanna Zeppa Dip , Gerald F. Watts DSc, PhD, DM

{"title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","authors":"Claudia Stefanutti MD, PhD , Dick C. Chan PhD , Giovanna Zeppa Dip , Gerald F. Watts DSc, PhD, DM","doi":"10.1016/j.jacl.2024.05.006","DOIUrl":"10.1016/j.jacl.2024.05.006","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Evinacumab is an inhibitor of angiopoietin-like 3 protein (ANGPTL3) that offers a new approach for correcting high low-density lipoprotein-cholesterol (LDL-C) and may reduce the need or frequency for lipoprotein apheresis (LA) in patients with homozygous familial hypercholesterolemia (HoFH).</div></div><div><h3>OBJECTIVE</h3><div>We aimed to investigate the long-term efficacy and safety of evinacumab in patients with HoFH aged between 14 and 63 years on and off LA in real-world clinical practice.</div></div><div><h3>METHODS</h3><div>Evinacumab was administrated intravenously (15 mg /kg every 4 weeks) for the first 24 months in 7 patients with genetically confirmed HoFH, receiving best standard of lipid-lowering treatment and LA, followed by a subsequent compassionate extension period of approximately 12-month treatment with evinacumab without LA. Patient experience of evinacumab and health-related EuroQol (EQ-5D-3L) quality of life questionnaire were also assessed.</div></div><div><h3>RESULTS</h3><div>Compared with baseline, evinacumab resulted in sustained reductions in plasma LDL-C concentration of -43.4% and -54.2% at 30 and 36 months, respectively. All 7 HoFH patients achieved an LDL-C reduction >30% with 3 patients having on-treatment LDL-C level < 2.5 mmol/L (96 mg/dL). Evinacumab was well-tolerated, with no major adverse events reported or significant changes in liver enzyme concentrations. All FH patients agreed that evinacumab was acceptable and less physically demanding than LA. The mean EQ- utility score and visual analogue score were 0.966 and 78.6, respectively, which are comparable to the Italian general population.</div></div><div><h3>CONCLUSIONS</h3><div>Our findings suggest that evinacumab is a safe and effective treatment for high LDL-C that is acceptable to HoFH patients receiving and not receiving LA.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 5","pages":"Pages e817-e824"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141531464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0